Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desflurane
Drug ID BADD_D00611
Description Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as [methoxyflurane], [sevoflurane], [enflurane], or [isoflurane].[A226390,A39015,A226893]. It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.[L30285]
Indications and Usage Desflurane is indicated for the induction and maintenance of anesthesia in adults, as well as the maintenance of anesthesia in pediatric patients.[L30285]
Marketing Status approved
ATC Code N01AB07
DrugBank ID DB01189
KEGG ID D00546
MeSH ID D000077335
PubChem ID 42113
TTD Drug ID D0H4GN
NDC Product Code 0404-9961; 52584-641; 66794-021; 0781-6172; 10019-641; 57884-0028; 10019-644; 10019-646
UNII CRS35BZ94Q
Synonyms Desflurane | 1,2,2,2-Tetrafluoroethyl difluoromethyl ether | I 653 | I-653 | I653 | Suprane
Chemical Information
Molecular Formula C3H2F6O
CAS Registry Number 57041-67-5
SMILES C(C(F)(F)F)(OC(F)F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypokalaemia14.05.03.002--
Hypotension24.06.03.0020.000268%
Hypoxia22.02.02.003--
Infection11.01.08.002---
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030---
Keratitis06.04.02.002--
Laryngospasm22.04.02.002--
Light anaesthesia25.01.03.003---
Liver disorder09.01.08.001---
Liver function test abnormal13.03.04.030---
Malaise08.01.01.003--
Malignant hypertension24.08.01.002---
Metabolic acidosis14.01.01.003---
Migraine17.14.02.001; 24.03.05.003---
Muscle rigidity15.05.04.001; 17.05.02.005---
Myalgia15.05.02.001--
Myocardial infarction02.02.02.007; 24.04.04.009--
Myocardial ischaemia02.02.02.008; 24.04.04.010---
Nausea07.01.07.0010.000911%
Nervous system disorder17.02.10.001---
Nodal arrhythmia02.03.03.020---
Ocular hyperaemia06.04.05.004---
Oxygen saturation decreased13.02.01.004---
Palpitations02.11.04.012--
Pancreatitis acute07.18.01.002---
Pharyngitis07.05.07.004; 11.01.13.003; 22.07.03.004--
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Renal failure20.01.03.005---
Respiratory arrest22.02.01.009---
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene